AB239291
Anti-HLA DR + HLA DP antibody [MEM-136] conjugated to APC - suitable for flow cytometry, and reacts with human samples. Clone [MEM-136] is a mouse monoclonal antibody.
Design your panel with our interactive flow cytometry panel builder. Click here.
Design your panel with our interactive flow cytometry panel builder. Click here.
1 이미지
- Flow Cyt
Supplier Data
Flow Cytometry - APC Anti-HLA DR + HLA DP antibody [MEM-136] (AB239291)
Flow cytometric analysis of human peripheral blood labeling HLA DR + HLA DP with ab239291. Surface staining. Gated on leukocytes.
Reactivity 정보
{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "10 µL for 10^6 Cells", "FlowCyt-species-notes": "<p>(or 100 μl of whole blood).</p>" } } }
특성 및 보관 정보
제형
Liquid
Purification 테크닉
Size-exclusion chromatography
Purification 관련 사항
Purified antibody is conjugated with cross-linked Allophycocyanin (APC) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
보관 버퍼
pH: 7.4 Preservative: 0.0975% Sodium azide Constituents: PBS
배송 시 보관 조건
Blue Ice
적절한 단기 보관 조건
+4°C
적절한 장기 보관 조건
+4°C
보관 정보
Store in the dark
제품 프로토콜
For this product, it's our understanding that no specific protocols are required. You can visit:
- Visit the General protocols
- Visit the Troubleshooting
타겟 정보
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
Additional targets
HLA-DRB4
대체 명칭 보기
HLA-DP1B, HLA-DPB1, MHC class II antigen DPB1, MHC class II antigen DRB4, HLA-DRB4
제품이 사용된 논문 (1)
Recent publications for all applications. Explore the 전체 목록 and refine your search
Journal of nanobiotechnology 22:803 PubMed39734237
2024
Targeting AURKA with multifunctional nanoparticles in CRPC therapy.
Applications
Unspecified application
Species
Unspecified reactive species
Bin Deng,Binghu Ke,Qixing Tian,Yukui Gao,Qiliang Zhai,Wenqiang Zhang
Product promise
저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.
자세한 내용은 이용 약관을 확인해 주세요.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com